Lucas P. Kwiyukwa

Lucas P. Kwiyukwa

Auto-generated profile, based on publicly available information

Lucas P. Kwiyukwa

Department of Chemistry, College of Natural and Applied Sciences, University of Dar es Salaam, P.O. Box 35061, Dar es Salaam, Tanzania

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2025 in Journal of Molecular Liquids
Verified
Journal Article
Open access
LKLucas P. Kwiyukwa
Lucas P. Kwiyukwa
LPLucas Paul
Lucas Paul
SMSixberth Mlowe
Sixberth Mlowe
SMSilvia J. Mushi
Silvia J. Mushi
GKGrace A. Kinunda
Grace A. Kinunda
Andrew PaluchAndrew Paluch
Andrew Paluch

7 February 2026 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Open access
MMMwashi F. Misungwi
Mwashi F. Misungwi
GDGeradius Deogratias
Geradius Deogratias
LKLucas Kwiyukwa
Lucas Kwiyukwa
SMSixberth Mlowe
Sixberth Mlowe
Andrew PaluchAndrew Paluch
Andrew Paluch
LPLucas Paula
Lucas Paula
Type 2 diabetes (T2D) is a chronic metabolic disorder managed by drugs like the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin. Due to associated adverse effects, the search for safer benzyl C-analogues is warranted. In this in silico study, nine novel analogues (A1-A9) and a reference compound (A10) were evaluated as potential SGLT2 inhibitors. All compounds satisfied drug-likeness criteria and exhibited favourable ADMET profiles, with five classified as toxicity class V. Molecular docking and 300ns molecular dynamics (MD) simulations identified A1 as the most promising candidate. A1 consistently demonstrated the most favourable binding free energy (MM/GBSA: -152.86±16.27kJ/mol) compared to A10 (-130.06±11.63kJ/mol), driven by van der Waals and electrostatic interactions. Furthermore, A1 induced superior dynamic stability, characterized by lower RMSD (0.268±0.023nm), reduced SASA (236.93±3.65nm2), and restricted collective motions (PCA). Crucially, the computational ranking strongly correlated with available in vitro data, where A1 exhibited the highest inhibitory potency (IC50=0.64nM). These combined findings suggest that compound A1 is a promising candidate, which warrants further experimental validation for T2D treatment.